Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist

European Journal of Pharmacology

Volumn 357, Issue 1, 1998, Pages 53-60

  Tanaka, Takao ^a   Fukuta, Yoshihisa ^a   Higashino, Raita ^a   Sato, Ryuichi ^a   Nomura, Yosuke ^a   Fukuda, Youichi ^a   Ito, Shigeru ^a   Takei, Mineo ^a   Kurimoto, Tadashi ^a   Tamaki, Hajime ^a  

^a Zeria Pharmaceutical   (Japan)

Author keywords

Indan derivative; Platelet aggregation; Pulmonary thromboembolism; Thromboxane A2 receptor antagonist; Z 335

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; INDAN DERIVATIVE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; Z 335;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG EMBOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE; THROMBOSIS;

EID: 0032508465     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00540-8     Document Type: Article

References (27)

1. 2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J. Biol. Chem. 268:1993;17397-17403.
2. Darius H., Lefer A.M. Blockade of thromboxane and the prevention of eicosanoid-induced sudden death in mice. Proc. Soc. Exp. Biol. Med. 180:1985;364-368.
3. 2 receptor subtypes: a radioligand binding study of human platelets. J. Clin. Invest. 84:1989;1883-1891.
4. 2. Science. 193:1976;1135-1137.
5. 2-prostaglandin endoperoxide receptor activation in vivo. J. Clin. Invest. 77:1986;496-502.
6. Goldman G., Welbourn R., Klausner J.M., Valeri C.R., Shepro D., Hechtman H.B. Thromboxane mediates diapedesis after ischemia by activation of neutrophil adhesion receptors interacting with basally expressed intercellular adhesion molecule-1. Circ. Res. 68:1991;1013-1019.
7. 2 and serotonin are possible mediators. Circulation. 79:1989;154-166.
8. Harris D.N., Michel I.M., Goldenberg H.J., Hartl K.S., Allen G.T., Steinbacher T.E., Schumacher W.A., Han W.C., Hall S.E., Floyd D.M., Ogletree M.L. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ-33261 and SQ-33552. J. Pharmacol. Exp. Ther. 261:1992;131-137.
9. 2 receptor. Nature. 349:1991;617-620.
10. 60 to Leu mutation. J. Clin. Invest. 97:1996;949-956.
11. 2. Prostaglandins Leukotrienes Essent. Fatty Acids. 51:1994;81-86.
12. 2 production. Biochem. Pharmacol. 31:1982;1158-1160.
13. Igawa T., Tani T., Chijiwa T., Shiragiku T., Shimidzu S., Kawamura K., Kato S., Unemi F., Kimura Y. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb. Res. 57:1990;617-623.
14. 2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells. Eur. J. Pharmacol. 262:1994;113-123.
15. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim.-Forsch. 35:1985;1144-1149.
16. 2/prostaglandin endoperoxide receptor antagonist. J. Cardiovasc. Pharmacol. 21:1993;441-447.
17. 2 in thrombus formation in the hamster cheek pouch in vivo. Prostaglandins. 28:1984;29-41.
18. Meyers K.M., Seachord C.L., Holmsen H., Smith J.B., Prieur D.J. A dominant role of thromboxane formation in secondary aggregation of platelets. Nature. 282:1979;331-333.
19. Patscheke H., Stegmeier K., Muller Beckmann B., Sponer G., Staiger C., Neugebauer G. Inhibitory effects of the selective thromboxane receptor antagonist BM-13177 on platelet aggregation, vasoconstriction and sudden death. Biomed. Biochim. Acta. 43:1984;S312-S318.
20. 2 and vascular smooth muscle cell proliferation. Hypertension. 26:1995;771-780.
21. Saitoh S., Saito T., Otake A., Owada T., Mitsugi M., Hashimoto H., Maruyama Y. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler. Thromb. 13:1993;563-570.
22. 2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation. 92:1995;3194-3200.
23. Schumacher W.A., Heran C.L., Steinbacher T.E., Youssef S., Ogletree M.L. Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. J. Cardiovasc. Pharmacol. 22:1993;526-533.
24. 2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation. 62:1980;V19-V25.
25. 2 analogues in human platelets: discrimination of two binding sites linked to distinct systems. J. Biol. Chem. 265:1990;6836-6844.
26. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313-320.
27. 2 receptor from human blood platelets. J. Biol. Chem. 264:1989;16496-16501.